Disease onset forecasting on Patient EHR dataset Prostate Cancer 2-year horizon (test)
91AUROCRAVEN
Evaluation results
| Method | Links | ||
|---|---|---|---|
| RAVENEvaluation protocol=Zero-shot, Inference method=Single forward pass2026.03 | 91 | 2.2 | |
| BERT (FT)Evaluation protocol=Supervised (Fine-tuned)2026.03 | 90.5 | 2.2 | |
| SeqLossEvaluation protocol=Zero-shot, Inference method=Monte Carlo rollouts (R=100)2026.03 | 80.1 | 1.7 | |
| MulticlassEvaluation protocol=Zero-shot, Inference method=Monte Carlo rollouts (R=100)2026.03 | 79.9 | 1.7 | |
| EGEEvaluation protocol=Zero-shot, Inference method=Monte Carlo rollouts (R=100)2026.03 | 74.3 | 0.8 |